{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T02:52:31Z","timestamp":1793847151930,"version":"4.6.1"},"reference-count":137,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10637-025-01513-y","type":"journal-article","created":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T15:03:48Z","timestamp":1740755028000},"page":"377-393","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["From development to clinical success: the journey of established and next-generation BTK inhibitors"],"prefix":"10.1007","volume":"43","author":[{"given":"Shivani","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abha","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"1","key":"1513_CR1","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/j.1600-065X.1994.tb00849.x","volume":"138","author":"DJ Rawlings","year":"1994","unstructured":"Rawlings DJ, Witte ON (1994) Bruton\u2019s tyrosine kinase is a key regulator in B-cell development. Immunol Rev 138(1):105\u2013119. https:\/\/doi.org\/10.1111\/j.1600-065X.1994.tb00849.x","journal-title":"Immunol Rev"},{"issue":"5","key":"1513_CR2","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/bies.1062","volume":"23","author":"CI Smith","year":"2001","unstructured":"Smith CI, Islam TC, Mattsson PT, Mohamed AJ, Nore BF, Vihinen M (2001) The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species, BioEssays News Rev. Mol Cell Dev Biol 23(5):436\u2013446. https:\/\/doi.org\/10.1002\/bies.1062","journal-title":"Mol Cell Dev Biol"},{"issue":"5","key":"1513_CR3","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1021\/cb4008524","volume":"9","author":"H Wu","year":"2014","unstructured":"Wu H et al (2014) Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma. ACS Chem Biol 9(5):1086\u20131091. https:\/\/doi.org\/10.1021\/cb4008524","journal-title":"ACS Chem Biol"},{"key":"1513_CR4","doi-asserted-by":"publisher","unstructured":"Hagemann T., Kwan SP. (1993) A BstNI polymorphism at the BTK locus in Xq21.3 \u2013 Xq22 Hum Mol Genet. 2(12):2201. https:\/\/doi.org\/10.1093\/hmg\/2.12.2201.","DOI":"10.1093\/hmg\/2.12.2201"},{"issue":"6409","key":"1513_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/361226a0","volume":"361","author":"D Vetrie","year":"1993","unstructured":"Vetrie D et al (1993) The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 361(6409):226\u2013233. https:\/\/doi.org\/10.1038\/361226a0","journal-title":"Nature"},{"issue":"6","key":"1513_CR6","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC (1952) Agammaglobulinemia. Pediatrics 9(6):722\u2013728. https:\/\/doi.org\/10.1542\/peds.9.6.722","journal-title":"Pediatrics"},{"issue":"4","key":"1513_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12098-015-2024-8","volume":"83","author":"D Suri","year":"2016","unstructured":"Suri D, Rawat A, Singh S (2016) X-linked agammaglobulinemia. Indian J Pediatr 83(4):331\u2013337. https:\/\/doi.org\/10.1007\/s12098-015-2024-8","journal-title":"Indian J Pediatr"},{"issue":"12","key":"1513_CR8","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1002\/humu.20410","volume":"27","author":"J V\u00e4liaho","year":"2006","unstructured":"V\u00e4liaho J, Smith CIE, Vihinen M (2006) BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat 27(12):1209\u20131217. https:\/\/doi.org\/10.1002\/humu.20410","journal-title":"Hum Mutat"},{"issue":"2","key":"1513_CR9","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/0092-8674(93)90667-f","volume":"72","author":"S Tsukada","year":"1993","unstructured":"Tsukada S et al (1993) Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia. Cell 72(2):279\u2013290. https:\/\/doi.org\/10.1016\/0092-8674(93)90667-f","journal-title":"Cell"},{"issue":"4","key":"1513_CR10","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1046\/j.1365-2567.2003.01624.x","volume":"108","author":"J Riggs","year":"2003","unstructured":"Riggs J, Howell K, Matechin B, Matlack R, Pennello A, Chiasson R (2003) X-chromosome-linked immune-deficient mice have B-1b cells. Immunology 108(4):440\u2013451. https:\/\/doi.org\/10.1046\/j.1365-2567.2003.01624.x","journal-title":"Immunology"},{"issue":"5","key":"1513_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/ni.2015","volume":"12","author":"X Liu","year":"2011","unstructured":"Liu X et al (2011) Intracellular MHC class II molecules promote TLR-triggered innate immune responses by maintaining activation of the kinase Btk. Nat Immunol 12(5):416\u2013424. https:\/\/doi.org\/10.1038\/ni.2015","journal-title":"Nat Immunol"},{"issue":"20","key":"1513_CR12","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S0960-9822(98)70471-3","volume":"8","author":"LS Quek","year":"1998","unstructured":"Quek LS, Bolen J, Watson SP (1998) A role for Bruton\u2019s tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 8(20):1137-S1. https:\/\/doi.org\/10.1016\/S0960-9822(98)70471-3","journal-title":"Curr Biol"},{"issue":"4","key":"1513_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/ni.2234","volume":"13","author":"F Honda","year":"2012","unstructured":"Honda F et al (2012) The kinase Btk negatively regulates the production of reactive oxygen species and stimulation-induced apoptosis in human neutrophils. Nat Immunol 13(4):369\u2013378. https:\/\/doi.org\/10.1038\/ni.2234","journal-title":"Nat Immunol"},{"issue":"12","key":"1513_CR14","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1002\/eji.1830241228","volume":"24","author":"HC Genevier","year":"1994","unstructured":"Genevier HC et al (1994) Expression of Bruton\u2019s tyrosine kinase protein within the B cell lineage. Eur J Immunol 24(12):3100\u20133105. https:\/\/doi.org\/10.1002\/eji.1830241228","journal-title":"Eur J Immunol"},{"issue":"4","key":"1513_CR15","first-page":"574","volume":"8","author":"FE Katz","year":"1994","unstructured":"Katz FE et al (1994) Expression of the X-linked agammaglobulinemia gene, btk in B-cell acute lymphoblastic leukemia. Leukemia 8(4):574\u2013577","journal-title":"Leukemia"},{"issue":"14","key":"1513_CR16","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.3390\/ijms22147641","volume":"22","author":"C Brullo","year":"2021","unstructured":"Brullo C, Villa C, Tasso B, Russo E, Spallarossa A (2021) Btk inhibitors: a medicinal chemistry and drug delivery perspective. Int J Mol Sci 22(14):7641. https:\/\/doi.org\/10.3390\/ijms22147641","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1513_CR17","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1080\/14656566.2021.1902988","volume":"22","author":"F Manji","year":"2021","unstructured":"Manji F, Puckrin R, Stewart DA (2021) Novel synthetic drugs for the treatment of non-Hodgkin lymphoma. Expert Opin Pharmacother 22(11):1417\u20131427. https:\/\/doi.org\/10.1080\/14656566.2021.1902988","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"1513_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000078339","volume":"134","author":"U Schmidt","year":"2004","unstructured":"Schmidt U, Boucheron N, Unger B, Ellmeier W (2004) The role of Tec family kinases in myeloid cells. Int Arch Allergy Immunol 134(1):65\u201378. https:\/\/doi.org\/10.1159\/000078339","journal-title":"Int Arch Allergy Immunol"},{"issue":"12","key":"1513_CR19","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1093\/emboj\/16.12.3396","volume":"16","author":"M Hyv\u00f6nen","year":"1997","unstructured":"Hyv\u00f6nen M, Saraste M (1997) Structure of the PH domain and Btk motif from Bruton\u2019s tyrosine kinase: molecular explanations for X-linked agammaglobulinaemia. EMBO J 16(12):3396\u20133404. https:\/\/doi.org\/10.1093\/emboj\/16.12.3396","journal-title":"EMBO J"},{"issue":"16","key":"1513_CR20","doi-asserted-by":"publisher","first-page":"10983","DOI":"10.1074\/jbc.274.16.10983","volume":"274","author":"P V\u00e1rnai","year":"1999","unstructured":"V\u00e1rnai P, Rother KI, Balla T (1999) Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton\u2019s tyrosine kinase pleckstrin homology domain visualized in single living cells. J Biol Chem 274(16):10983\u201310989. https:\/\/doi.org\/10.1074\/jbc.274.16.10983","journal-title":"J Biol Chem"},{"issue":"20","key":"1513_CR21","doi-asserted-by":"publisher","first-page":"5692","DOI":"10.1093\/emboj\/20.20.5692","volume":"20","author":"SW Kang","year":"2001","unstructured":"Kang SW et al (2001) PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization. EMBO J 20(20):5692\u20135702. https:\/\/doi.org\/10.1093\/emboj\/20.20.5692","journal-title":"EMBO J"},{"issue":"2\u20133","key":"1513_CR22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0014-5793(94)00783-7","volume":"350","author":"M Vihinen","year":"1994","unstructured":"Vihinen M, Nilsson L, Smith CI (1994) Tec homology (TH) adjacent to the PH domain. FEBS Lett 350(2\u20133):263\u2013265. https:\/\/doi.org\/10.1016\/0014-5793(94)00783-7","journal-title":"FEBS Lett"},{"issue":"5","key":"1513_CR23","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/s1074-7613(00)80417-3","volume":"4","author":"H Park","year":"1996","unstructured":"Park H et al (1996) Regulation of Btk function by a major autophosphorylation site within the SH3 domain. Immunity 4(5):515\u2013525. https:\/\/doi.org\/10.1016\/s1074-7613(00)80417-3","journal-title":"Immunity"},{"issue":"21","key":"1513_CR24","doi-asserted-by":"publisher","first-page":"11526","DOI":"10.1073\/pnas.94.21.11526","volume":"94","author":"MI Wahl","year":"1997","unstructured":"Wahl MI, Fluckiger AC, Kato RM, Park H, Witte ON, Rawlings DJ (1997) Phosphorylation of two regulatory tyrosine residues in the activation of Bruton\u2019s tyrosine kinase via alternative receptors. Proc Natl Acad Sci U S A 94(21):11526\u201311533. https:\/\/doi.org\/10.1073\/pnas.94.21.11526","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"1513_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/cmdc.200600221","volume":"2","author":"Z Pan","year":"2007","unstructured":"Pan Z et al (2007) Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase. ChemMedChem 2(1):58\u201361. https:\/\/doi.org\/10.1002\/cmdc.200600221","journal-title":"ChemMedChem"},{"issue":"3","key":"1513_CR26","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1124\/mol.116.107037","volume":"91","author":"AT Bender","year":"2017","unstructured":"Bender AT et al (2017) Ability of Bruton\u2019s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling. Mol Pharmacol 91(3):208\u2013219. https:\/\/doi.org\/10.1124\/mol.116.107037","journal-title":"Mol Pharmacol"},{"issue":"51","key":"1513_CR27","doi-asserted-by":"publisher","first-page":"40614","DOI":"10.1074\/jbc.M006952200","volume":"275","author":"AJ Mohamed","year":"2000","unstructured":"Mohamed AJ, Vargas L, Nore BF, Backesjo CM, Christensson B, Smith CI (2000) Nucleocytoplasmic shuttling of Bruton\u2019s tyrosine kinase. J Biol Chem 275(51):40614\u201340619. https:\/\/doi.org\/10.1074\/jbc.M006952200","journal-title":"J Biol Chem"},{"issue":"12","key":"1513_CR28","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/sj.onc.1201308","volume":"15","author":"T Li","year":"1997","unstructured":"Li T, Rawlings DJ, Park H, Kato RM, Witte ON, Satterthwaite AB (1997) Constitutive membrane association potentiates activation of Bruton tyrosine kinase. Oncogene 15(12):1375\u20131383. https:\/\/doi.org\/10.1038\/sj.onc.1201308","journal-title":"Oncogene"},{"issue":"25","key":"1513_CR29","doi-asserted-by":"publisher","first-page":"13820","DOI":"10.1073\/pnas.94.25.13820","volume":"94","author":"Z Li","year":"1997","unstructured":"Li Z, Wahl MI, Eguinoa A, Stephens LR, Hawkins PT, Witte ON (1997) Phosphatidylinositol 3-kinase-\u03b3 activates Bruton\u2019s tyrosine kinase in concert with Src family kinases. Proc Natl Acad Sci U S A 94(25):13820\u201313825","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1513_CR30","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1084\/jem.188.7.1297","volume":"188","author":"A Jiang","year":"1998","unstructured":"Jiang A, Craxton A, Kurosaki T, Clark EA (1998) Different protein tyrosine kinases are required for B cell antigen receptor\u2013mediated activation of extracellular signal\u2013regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase. J Exp Med 188(7):1297\u20131306","journal-title":"J Exp Med"},{"issue":"10","key":"1513_CR31","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1084\/jem.191.10.1745","volume":"191","author":"JB Petro","year":"2000","unstructured":"Petro JB, Rahman SMJ, Ballard DW, Khan WN (2000) Bruton\u2019s tyrosine kinase is required for activation of I\u03bab kinase and nuclear factor \u03bab in response to B cell receptor engagement. J Exp Med 191(10):1745\u20131754","journal-title":"J Exp Med"},{"issue":"32","key":"1513_CR32","doi-asserted-by":"publisher","first-page":"13247","DOI":"10.1073\/pnas.1110486108","volume":"108","author":"JR Hart","year":"2011","unstructured":"Hart JR, Liao L, Yates JR, Vogt PK (2011) Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci 108(32):13247\u201313252. https:\/\/doi.org\/10.1073\/pnas.1110486108","journal-title":"Proc Natl Acad Sci"},{"key":"1513_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3389\/fimmu.2019.00457","volume":"10","author":"K Hayakawa","year":"2019","unstructured":"Hayakawa K et al (2019) Crucial role of increased Arid3a at the pre-B and immature B cell stages for B1a cell generation. Front Immunol 10:457. https:\/\/doi.org\/10.3389\/fimmu.2019.00457","journal-title":"Front Immunol"},{"issue":"2","key":"1513_CR34","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1073\/pnas.94.2.604","volume":"94","author":"W Yang","year":"1997","unstructured":"Yang W, Desiderio S (1997) BAP-135, a target for Bruton\u2019s tyrosine kinase in response to B cell receptor engagement. Proc Natl Acad Sci U S A 94(2):604\u2013609","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"1513_CR35","doi-asserted-by":"publisher","first-page":"10966","DOI":"10.1073\/pnas.93.20.10966","volume":"93","author":"JS Anderson","year":"1996","unstructured":"Anderson JS, Teutsch M, Dong Z, Wortis HH (1996) An essential role for Bruton\u2019s [corrected] tyrosine kinase in the regulation of B-cell apoptosis. Proc Natl Acad Sci U S A 93(20):10966\u201310971. https:\/\/doi.org\/10.1073\/pnas.93.20.10966","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"1513_CR36","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1182\/blood-2011-12-397919","volume":"119","author":"LP Kil","year":"2012","unstructured":"Kil LP et al (2012) Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice. Blood 119(16):3744\u20133756. https:\/\/doi.org\/10.1182\/blood-2011-12-397919","journal-title":"Blood"},{"issue":"22","key":"1513_CR37","doi-asserted-by":"publisher","first-page":"10606","DOI":"10.1073\/pnas.91.22.10606","volume":"91","author":"Y Aoki","year":"1994","unstructured":"Aoki Y, Isselbacher KJ, Pillai S (1994) Bruton tyrosine kinase is tyrosine phosphorylated and activated in pre-B lymphocytes and receptor-ligated B cells. Proc Natl Acad Sci U S A 91(22):10606\u201310609. https:\/\/doi.org\/10.1073\/pnas.91.22.10606","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"39","key":"1513_CR38","doi-asserted-by":"publisher","first-page":"23857","DOI":"10.1016\/S0021-9258(19)51014-6","volume":"269","author":"M de Weers","year":"1994","unstructured":"de Weers M et al (1994) B-cell antigen receptor stimulation activates the human Bruton\u2019s tyrosine kinase, which is deficient in X-linked agammaglobulinemia. J Biol Chem 269(39):23857\u201323860. https:\/\/doi.org\/10.1016\/S0021-9258(19)51014-6","journal-title":"J Biol Chem"},{"issue":"5","key":"1513_CR39","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.it.2004.02.011","volume":"25","author":"RW Hendriks","year":"2004","unstructured":"Hendriks RW, Middendorp S (2004) The pre-BCR checkpoint as a cell-autonomous proliferation switch. Trends Immunol 25(5):249\u2013256. https:\/\/doi.org\/10.1016\/j.it.2004.02.011","journal-title":"Trends Immunol"},{"issue":"1","key":"1513_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/ijms25010010","volume":"25","author":"A Tkachenko","year":"2023","unstructured":"Tkachenko A, Kupcova K, Havranek O (2023) B-cell receptor signaling and beyond: the role of Ig\u03b1 (CD79a)\/Ig\u03b2 (CD79b) in normal and malignant B cells. Int J Mol Sci 25(1):10. https:\/\/doi.org\/10.3390\/ijms25010010","journal-title":"Int J Mol Sci"},{"key":"1513_CR41","doi-asserted-by":"publisher","first-page":"1339620","DOI":"10.3389\/fonc.2024.1339620","volume":"14","author":"VK Schmid","year":"2024","unstructured":"Schmid VK, Hobeika E (2024) B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia. Front Oncol 14:1339620. https:\/\/doi.org\/10.3389\/fonc.2024.1339620","journal-title":"Front Oncol"},{"issue":"11","key":"1513_CR42","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.4049\/jimmunol.2100218","volume":"207","author":"JM DeLuca","year":"2021","unstructured":"DeLuca JM, Murphy MK, Wang X, Wilson TJ (2021) FCRL1 regulates B cell receptor\u2013induced ERK activation through GRB2. J Immunol 207(11):2688\u20132698. https:\/\/doi.org\/10.4049\/jimmunol.2100218","journal-title":"J Immunol"},{"issue":"19","key":"1513_CR43","doi-asserted-by":"publisher","first-page":"16201","DOI":"10.1074\/jbc.M100873200","volume":"276","author":"K Saito","year":"2001","unstructured":"Saito K, Scharenberg AM, Kinet JP (2001) Interaction between the Btk PH domain and phosphatidylinositol-3,4,5-trisphosphate directly regulates Btk. J Biol Chem 276(19):16201\u201316206. https:\/\/doi.org\/10.1074\/jbc.M100873200","journal-title":"J Biol Chem"},{"issue":"22","key":"1513_CR44","doi-asserted-by":"publisher","first-page":"9986","DOI":"10.1128\/MCB.24.22.9986-9999.2004","volume":"24","author":"YJ Kim","year":"2004","unstructured":"Kim YJ, Sekiya F, Poulin B, Bae YS, Rhee SG (2004) Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-gamma2. Mol Cell Biol 24(22):9986\u20139999. https:\/\/doi.org\/10.1128\/MCB.24.22.9986-9999.2004","journal-title":"Mol Cell Biol"},{"issue":"11","key":"1513_CR45","doi-asserted-by":"publisher","first-page":"e13122","DOI":"10.1111\/cpr.13122","volume":"54","author":"R Ren","year":"2021","unstructured":"Ren R, Guo J, Chen Y, Zhang Y, Chen L, Xiong W (2021) The role of Ca2+\/calcineurin\/NFAT signalling pathway in osteoblastogenesis. Cell Prolif 54(11):e13122. https:\/\/doi.org\/10.1111\/cpr.13122","journal-title":"Cell Prolif"},{"issue":"10","key":"1513_CR46","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1084\/jem.191.10.1735","volume":"191","author":"UD Bajpai","year":"2000","unstructured":"Bajpai UD, Zhang K, Teutsch M, Sen R, Wortis HH (2000) Bruton\u2019s tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med 191(10):1735\u20131744. https:\/\/doi.org\/10.1084\/jem.191.10.1735","journal-title":"J Exp Med"},{"issue":"3","key":"1513_CR47","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning BD, Toker A (2017) AKT\/PKB signaling: navigating the network. Cell 169(3):381\u2013405. https:\/\/doi.org\/10.1016\/j.cell.2017.04.001","journal-title":"Cell"},{"issue":"7","key":"1513_CR48","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1084\/jem.188.7.1287","volume":"188","author":"A Hashimoto","year":"1998","unstructured":"Hashimoto A et al (1998) Involvement of guanosine triphosphatases and phospholipase C-gamma2 in extracellular signal-regulated kinase, c-Jun NH2-terminal kinase, and p38 mitogen-activated protein kinase activation by the B cell antigen receptor. J Exp Med 188(7):1287\u20131295. https:\/\/doi.org\/10.1084\/jem.188.7.1287","journal-title":"J Exp Med"},{"issue":"6","key":"1513_CR49","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1074\/jbc.M115.687251","volume":"291","author":"L Ren","year":"2016","unstructured":"Ren L et al (2016) Analysis of the effects of the Bruton\u2019s tyrosine kinase (Btk) inhibitor ibrutinib on monocyte Fc\u03b3 receptor (Fc\u03b3R) function *. J Biol Chem 291(6):3043\u20133052. https:\/\/doi.org\/10.1074\/jbc.M115.687251","journal-title":"J Biol Chem"},{"issue":"51","key":"1513_CR50","doi-asserted-by":"publisher","first-page":"36953","DOI":"10.1074\/jbc.M707682200","volume":"282","author":"SL Doyle","year":"2007","unstructured":"Doyle SL, Jefferies CA, Feighery C, O\u2019Neill LAJ (2007) Signaling by Toll-like receptors 8 and 9 requires Bruton\u2019s tyrosine kinase. J Biol Chem 282(51):36953\u201336960. https:\/\/doi.org\/10.1074\/jbc.M707682200","journal-title":"J Biol Chem"},{"issue":"10","key":"1513_CR51","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1084\/jem.20011866","volume":"198","author":"M Spaargaren","year":"2003","unstructured":"Spaargaren M et al (2003) The B cell antigen receptor controls integrin activity through Btk and PLC\u03b32. J Exp Med 198(10):1539\u20131550. https:\/\/doi.org\/10.1084\/jem.20011866","journal-title":"J Exp Med"},{"issue":"15","key":"1513_CR52","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1182\/blood-2009-11-254185","volume":"115","author":"H Mueller","year":"2010","unstructured":"Mueller H et al (2010) Tyrosine kinase Btk regulates E-selectin\u2013mediated integrin activation and neutrophil recruitment by controlling phospholipase C (PLC) \u03b32 and PI3K\u03b3 pathways. Blood 115(15):3118\u20133127. https:\/\/doi.org\/10.1182\/blood-2009-11-254185","journal-title":"Blood"},{"key":"1513_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1600-065X.2000.imr017504.x","volume":"175","author":"AB Satterthwaite","year":"2000","unstructured":"Satterthwaite AB, Witte ON (2000) The role of Bruton\u2019s tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev 175:120\u2013127","journal-title":"Immunol Rev"},{"key":"1513_CR54","doi-asserted-by":"publisher","unstructured":"Sharma S, Orlowski G, Song W. (2009) Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells,\u201d J. Immunol. Baltim. Md 1950 182(1):329\u2013339 https:\/\/doi.org\/10.4049\/jimmunol.182.1.329","DOI":"10.4049\/jimmunol.182.1.329"},{"issue":"2","key":"1513_CR55","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","volume":"117","author":"Y Herishanu","year":"2011","unstructured":"Herishanu Y et al (2011) The lymph node microenvironment promotes B-cell receptor signaling, NF-\u03baB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117(2):563\u2013574. https:\/\/doi.org\/10.1182\/blood-2010-05-284984","journal-title":"Blood"},{"issue":"42","key":"1513_CR56","doi-asserted-by":"publisher","first-page":"71981","DOI":"10.18632\/oncotarget.18234","volume":"8","author":"SP Singh","year":"2017","unstructured":"Singh SP et al (2017) Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signalling. Oncotarget 8(42):71981\u201371995. https:\/\/doi.org\/10.18632\/oncotarget.18234","journal-title":"Oncotarget"},{"issue":"11","key":"1513_CR57","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MFM de Rooij","year":"2012","unstructured":"de Rooij MFM et al (2012) The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119(11):2590\u20132594. https:\/\/doi.org\/10.1182\/blood-2011-11-390989","journal-title":"Blood"},{"issue":"5","key":"1513_CR58","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1182\/blood-2011-10-386417","volume":"119","author":"S Ponader","year":"2012","unstructured":"Ponader S et al (2012) The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119(5):1182\u20131189. https:\/\/doi.org\/10.1182\/blood-2011-10-386417","journal-title":"Blood"},{"issue":"11","key":"1513_CR59","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1200\/JCO.2015.63.5904","volume":"34","author":"CY Cheah","year":"2016","unstructured":"Cheah CY, Seymour JF, Wang ML (2016) Mantle cell lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 34(11):1256\u20131269. https:\/\/doi.org\/10.1200\/JCO.2015.63.5904","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"1513_CR60","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.leukres.2013.07.028","volume":"37","author":"M Cinar","year":"2013","unstructured":"Cinar M, Hamedani F, Mo Z, Cinar B, Amin HM, Alkan S (2013) Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk Res 37(10):1271\u20131277. https:\/\/doi.org\/10.1016\/j.leukres.2013.07.028","journal-title":"Leuk Res"},{"issue":"2","key":"1513_CR61","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s13402-011-0019-7","volume":"34","author":"C Pighi","year":"2011","unstructured":"Pighi C et al (2011) Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol Dordr Neth 34(2):141\u2013153. https:\/\/doi.org\/10.1007\/s13402-011-0019-7","journal-title":"Cell Oncol Dordr Neth"},{"issue":"6769","key":"1513_CR62","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503\u2013511. https:\/\/doi.org\/10.1038\/35000501","journal-title":"Nature"},{"issue":"14","key":"1513_CR63","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1182\/blood-2013-02-482125","volume":"122","author":"BY Chang","year":"2013","unstructured":"Chang BY et al (2013) Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 122(14):2412\u20132424. https:\/\/doi.org\/10.1182\/blood-2013-02-482125","journal-title":"Blood"},{"issue":"7","key":"1513_CR64","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1182\/blood-2014-04-566778","volume":"125","author":"J Iqbal","year":"2015","unstructured":"Iqbal J et al (2015) Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood 125(7):1137\u20131145. https:\/\/doi.org\/10.1182\/blood-2014-04-566778","journal-title":"Blood"},{"key":"1513_CR65","doi-asserted-by":"publisher","first-page":"815325","DOI":"10.1155\/2013\/815325","volume":"2013","author":"S Janz","year":"2013","unstructured":"Janz S (2013) Waldenstr\u00f6m macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. ISRN Hematol 2013:815325. https:\/\/doi.org\/10.1155\/2013\/815325","journal-title":"ISRN Hematol"},{"issue":"4","key":"1513_CR66","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13543776.2019.1594777","volume":"29","author":"Y Feng","year":"2019","unstructured":"Feng Y, Duan W, Cu X, Liang C, Xin M (2019) Bruton\u2019s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010\u20132018). Expert Opin Ther Pat 29(4):217\u2013241. https:\/\/doi.org\/10.1080\/13543776.2019.1594777","journal-title":"Expert Opin Ther Pat"},{"issue":"11","key":"1513_CR67","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","volume":"123","author":"ZR Hunter","year":"2014","unstructured":"Hunter ZR et al (2014) The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123(11):1637\u20131646. https:\/\/doi.org\/10.1182\/blood-2013-09-525808","journal-title":"Blood"},{"issue":"1","key":"1513_CR68","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1182\/blood-2007-12-129395","volume":"112","author":"HT Ngo","year":"2008","unstructured":"Ngo HT et al (2008) SDF-1\/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 112(1):150\u2013158. https:\/\/doi.org\/10.1182\/blood-2007-12-129395","journal-title":"Blood"},{"key":"1513_CR69","doi-asserted-by":"publisher","unstructured":"Elbezanti WO et al. (2022) Development of a novel Bruton\u2019s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells. Front Pharmacol. 13. https:\/\/doi.org\/10.3389\/fphar.2022.894535.","DOI":"10.3389\/fphar.2022.894535"},{"issue":"3","key":"1513_CR70","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1158\/0008-5472.CAN-14-2362","volume":"75","author":"Y Yang","year":"2015","unstructured":"Yang Y et al (2015) Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. Cancer Res 75(3):594\u2013604. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-2362","journal-title":"Cancer Res"},{"issue":"9","key":"1513_CR71","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1182\/blood-2011-12-396853","volume":"120","author":"Y-T Tai","year":"2012","unstructured":"Tai Y-T et al (2012) Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 120(9):1877\u20131887. https:\/\/doi.org\/10.1182\/blood-2011-12-396853","journal-title":"Blood"},{"issue":"6","key":"1513_CR72","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.bmcl.2015.01.032","volume":"25","author":"WB Young","year":"2015","unstructured":"Young WB et al (2015) Potent and selective Bruton\u2019s tyrosine kinase inhibitors: discovery of GDC-0834. Bioorg Med Chem Lett 25(6):1333\u20131337. https:\/\/doi.org\/10.1016\/j.bmcl.2015.01.032","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"1513_CR73","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3324\/haematol.2011.054080","volume":"97","author":"Q Yan","year":"2012","unstructured":"Yan Q et al (2012) BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica 97(4):595\u2013598. https:\/\/doi.org\/10.3324\/haematol.2011.054080","journal-title":"Haematologica"},{"issue":"14","key":"1513_CR74","doi-asserted-by":"publisher","first-page":"9587","DOI":"10.1074\/jbc.274.14.9587","volume":"274","author":"S Mahajan","year":"1999","unstructured":"Mahajan S et al (1999) Rational design and synthesis of a novel anti-leukemic agent targeting Bruton\u2019s tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide]. J Biol Chem 274(14):9587\u20139599. https:\/\/doi.org\/10.1074\/jbc.274.14.9587","journal-title":"J Biol Chem"},{"issue":"10","key":"1513_CR75","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1182\/blood.v98.10.3050","volume":"98","author":"A Bernal","year":"2001","unstructured":"Bernal A et al (2001) Survival of leukemic B cells promoted by engagement of the antigen receptor. Blood 98(10):3050\u20133057. https:\/\/doi.org\/10.1182\/blood.v98.10.3050","journal-title":"Blood"},{"key":"1513_CR76","doi-asserted-by":"publisher","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE (2021) Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol 9:630942. https:\/\/doi.org\/10.3389\/fcell.2021.630942","journal-title":"Front Cell Dev Biol"},{"key":"1513_CR77","doi-asserted-by":"publisher","unstructured":"Tasso B, Spallarossa A, Russo E, Brullo C. (2021) The development of BTK inhibitors: a five-year update. Molecules, 26(23). https:\/\/doi.org\/10.3390\/molecules26237411.","DOI":"10.3390\/molecules26237411"},{"key":"1513_CR78","doi-asserted-by":"publisher","unstructured":"de Claro RA et al. (2015) FDA approval: ibrutinib for patients with previously treated mantle cell lymphoma and previously treated chronic lymphocytic leukaemia. Clin Cancer Res Off. J Am Assoc Cancer Res. 21(16):3586\u20133590 https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2225","DOI":"10.1158\/1078-0432.CCR-14-2225"},{"issue":"4","key":"1513_CR79","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","volume":"374","author":"JC Byrd","year":"2016","unstructured":"Byrd JC et al (2016) Acalabrutinib (ACP-196) in Relapsed chronic lymphocytic leukemia. N Engl J Med 374(4):323\u2013332. https:\/\/doi.org\/10.1056\/NEJMoa1509981","journal-title":"N Engl J Med"},{"issue":"11","key":"1513_CR80","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS et al (2019) Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood 134(11):851\u2013859. https:\/\/doi.org\/10.1182\/blood.2019001160","journal-title":"Blood"},{"key":"1513_CR81","unstructured":"C. for D. E. and Research, FDA grants accelerated approval to zanubrutinib for relapsed or refractory follicular lymphoma, FDA, Aug. 2024, Accessed: Aug. 13, 2024. [Online]. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zanubrutinib-relapsed-or-refractory-follicular-lymphoma"},{"key":"1513_CR82","doi-asserted-by":"publisher","unstructured":"Tam CS et al. (2020) A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study\u201d, https:\/\/doi.org\/10.1182\/blood.2020006844.","DOI":"10.1182\/blood.2020006844"},{"issue":"4","key":"1513_CR83","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR et al (2023) Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 388(4):319\u2013332. https:\/\/doi.org\/10.1056\/NEJMoa2211582","journal-title":"N Engl J Med"},{"issue":"8","key":"1513_CR84","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40265-020-01318-8","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S (2020) Tirabrutinib: first approval. Drugs 80(8):835\u2013840. https:\/\/doi.org\/10.1007\/s40265-020-01318-8","journal-title":"Drugs"},{"key":"1513_CR85","doi-asserted-by":"publisher","unstructured":"YH et al. (2024) Three-year follow-up analysis of phase 1\/2 study on tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma,\u201d Neuro-Oncol. Adv. 6(1). https:\/\/doi.org\/10.1093\/noajnl\/vdae037.","DOI":"10.1093\/noajnl\/vdae037"},{"issue":"1","key":"1513_CR86","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","volume":"23","author":"Y Narita","year":"2021","unstructured":"Narita Y et al (2021) Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma. Neuro-Oncol 23(1):122\u2013133. https:\/\/doi.org\/10.1093\/neuonc\/noaa145","journal-title":"Neuro-Oncol"},{"key":"1513_CR87","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1182\/blood-2021-146491","volume":"138","author":"W Xu","year":"2021","unstructured":"Xu W et al (2021) Orelabrutinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma: updated long term results of phase II study. Blood 138:2638. https:\/\/doi.org\/10.1182\/blood-2021-146491","journal-title":"Blood"},{"issue":"16","key":"1513_CR88","doi-asserted-by":"publisher","first-page":"4349","DOI":"10.1182\/bloodadvances.2022009168","volume":"7","author":"L-J Deng","year":"2023","unstructured":"Deng L-J et al (2023) Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1\/2, open-label, multicenter, single-arm study. Blood Adv 7(16):4349\u20134357. https:\/\/doi.org\/10.1182\/bloodadvances.2022009168","journal-title":"Blood Adv"},{"key":"1513_CR89","unstructured":"Press Release | INNOCARE. Accessed: Oct. 06, 2024. [Online]. Available: https:\/\/www.innocarepharma.com\/en\/investor\/news"},{"issue":"4","key":"1513_CR90","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","volume":"81","author":"S Dhillon","year":"2021","unstructured":"Dhillon S (2021) Orelabrutinib: first approval. Drugs 81(4):503\u2013507. https:\/\/doi.org\/10.1007\/s40265-021-01482-5","journal-title":"Drugs"},{"issue":"6","key":"1513_CR91","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40265-023-01860-1","volume":"83","author":"SJ Keam","year":"2023","unstructured":"Keam SJ (2023) Pirtobrutinib: first approval. Drugs 83(6):547\u2013553. https:\/\/doi.org\/10.1007\/s40265-023-01860-1","journal-title":"Drugs"},{"issue":"24","key":"1513_CR92","doi-asserted-by":"publisher","first-page":"3988","DOI":"10.1200\/JCO.23.00562","volume":"41","author":"ML Wang","year":"2023","unstructured":"Wang ML et al (2023) Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma. J Clin Oncol 41(24):3988\u20133997. https:\/\/doi.org\/10.1200\/JCO.23.00562","journal-title":"J Clin Oncol"},{"issue":"1","key":"1513_CR93","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2300696","volume":"389","author":"AR Mato","year":"2023","unstructured":"Mato AR et al (2023) Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia. N Engl J Med 389(1):33\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2300696","journal-title":"N Engl J Med"},{"issue":"8","key":"1513_CR94","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa2114110","volume":"386","author":"E Wang","year":"2022","unstructured":"Wang E et al (2022) Mechanisms of resistance to noncovalent Bruton\u2019s tyrosine kinase inhibitors. N Engl J Med 386(8):735\u2013743. https:\/\/doi.org\/10.1056\/NEJMoa2114110","journal-title":"N Engl J Med"},{"issue":"6","key":"1513_CR95","doi-asserted-by":"publisher","first-page":"957","DOI":"10.2217\/fon.14.51","volume":"10","author":"MS Davids","year":"2014","unstructured":"Davids MS, Brown JR (2014) Ibrutinib: a first in class covalent inhibitor of Bruton\u2019s tyrosine kinase. Future Oncol Lond Engl 10(6):957\u2013967. https:\/\/doi.org\/10.2217\/fon.14.51","journal-title":"Future Oncol Lond Engl"},{"issue":"29","key":"1513_CR96","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA et al (2010) The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107(29):13075\u201313080. https:\/\/doi.org\/10.1073\/pnas.1004594107","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"23","key":"1513_CR97","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SEM Herman","year":"2011","unstructured":"Herman SEM et al (2011) Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23):6287\u20136296. https:\/\/doi.org\/10.1182\/blood-2011-01-328484","journal-title":"Blood"},{"issue":"6","key":"1513_CR98","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML et al (2013) Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6):507\u2013516. https:\/\/doi.org\/10.1056\/NEJMoa1306220","journal-title":"N Engl J Med"},{"issue":"1","key":"1513_CR99","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC et al (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369(1):32\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1215637","journal-title":"N Engl J Med"},{"key":"1513_CR100","doi-asserted-by":"publisher","unstructured":"Sharma A, Raut SS, Dhikale P, Khushboo, Mishra A. (2024) Navigating the landscape of cancer-induced thrombocytopenia: current challenges and emerging advances,\u201d in Industrial microbiology and biotechnology, P. Verma, Ed., Singapore: Springer Nature Singapore, 435\u2013463. https:\/\/doi.org\/10.1007\/978-981-97-6270-5_14.","DOI":"10.1007\/978-981-97-6270-5_14"},{"issue":"12","key":"1513_CR101","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T et al (2019) Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 94(12):1353\u20131363. https:\/\/doi.org\/10.1002\/ajh.25638","journal-title":"Am J Hematol"},{"key":"1513_CR102","unstructured":"\u201cIMBRUVICA\u00ae (ibrutinib) Approved by U.S. FDA for the first-line treatment of chronic lymphocytic leukemia,\u201d AbbVie News Center. Accessed: Jan. 28, 2025. [Online]. Available: https:\/\/news.abbvie.com\/2016-03-04-IMBRUVICA-ibrutinib-Approved-by-U-S-FDA-for-the-First-line-Treatment-of-Chronic-Lymphocytic-Leukemia"},{"key":"1513_CR103","doi-asserted-by":"publisher","first-page":"S342","DOI":"10.1016\/S2152-2650(24)01259-X","volume":"24","author":"J Burger","year":"2024","unstructured":"Burger J et al (2024) CLL-076 final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Clin Lymphoma Myeloma Leuk 24:S342\u2013S343. https:\/\/doi.org\/10.1016\/S2152-2650(24)01259-X","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"1513_CR104","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1182\/blood-2024-194156","volume":"144","author":"FT Awan","year":"2024","unstructured":"Awan FT et al (2024) Single-agent ibrutinib versus allogeneic hematopoietic cell transplantation for patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma and del(17p). Blood 144(Supplement 1):2178\u20132178. https:\/\/doi.org\/10.1182\/blood-2024-194156","journal-title":"Blood"},{"issue":"1","key":"1513_CR105","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani RH et al (2013) Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J Clin Oncol Off J Am Soc Clin Oncol 31(1):88\u201394. https:\/\/doi.org\/10.1200\/JCO.2012.42.7906","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1513_CR106","unstructured":"\u201cUpdate on IMBRUVICA\u00ae (ibrutinib) U.S. accelerated approvals for mantle cell lymphoma and marginal zone lymphoma indications,\u201d JNJ.com. Accessed: Oct. 06, 2024. [Online]. Available: https:\/\/www.jnj.com\/media-center\/press-releases\/update-on-imbruvica-ibrutinib-u-s-accelerated-approvals-for-mantle-cell-lymphoma-and-marginal-zone-lymphoma-indications"},{"issue":"2","key":"1513_CR107","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P (2021) Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia 35(2):312\u2013332. https:\/\/doi.org\/10.1038\/s41375-020-01072-6","journal-title":"Leukemia"},{"key":"1513_CR108","doi-asserted-by":"publisher","unstructured":"Wu J, Zhang M, Liu D. (2016) Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol.J Hematol Oncol. 9(21). https:\/\/doi.org\/10.1186\/s13045-016-0250-9.","DOI":"10.1186\/s13045-016-0250-9"},{"issue":"31","key":"1513_CR109","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC et al (2021) Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 39(31):3441\u20133452. https:\/\/doi.org\/10.1200\/JCO.21.01210","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"26","key":"1513_CR110","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1182\/blood.2023020240","volume":"141","author":"PA Thompson","year":"2023","unstructured":"Thompson PA, Tam CS (2023) Pirtobrutinib: a new hope for patients with BTK inhibitor\u2013refractory lymphoproliferative disorders. Blood 141(26):3137\u20133142. https:\/\/doi.org\/10.1182\/blood.2023020240","journal-title":"Blood"},{"issue":"20","key":"1513_CR111","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1182\/bloodadvances.2022008325","volume":"6","author":"P Blombery","year":"2022","unstructured":"Blombery P et al (2022) Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Adv 6(20):5589\u20135592. https:\/\/doi.org\/10.1182\/bloodadvances.2022008325","journal-title":"Blood Adv"},{"issue":"10","key":"1513_CR112","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1002\/art.41811","volume":"73","author":"D Isenberg","year":"2021","unstructured":"Isenberg D et al (2021) Efficacy, safety, and pharmacodynamic effects of the Bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol 73(10):1835\u20131846. https:\/\/doi.org\/10.1002\/art.41811","journal-title":"Arthritis Rheumatol"},{"issue":"17","key":"1513_CR113","doi-asserted-by":"publisher","first-page":"7643","DOI":"10.1021\/acs.jmedchem.9b00794","volume":"62","author":"RD Caldwell","year":"2019","unstructured":"Caldwell RD et al (2019) Discovery of evobrutinib: an oral, potent, and highly selective, covalent Bruton\u2019s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases. J Med Chem 62(17):7643\u20137655. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00794","journal-title":"J Med Chem"},{"key":"1513_CR114","doi-asserted-by":"publisher","unstructured":"Haselmayer P et al. (2019) Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models. J Immunol Baltim. Md 1950 202(10):2888\u20132906. https:\/\/doi.org\/10.4049\/jimmunol.1800583.","DOI":"10.4049\/jimmunol.1800583"},{"key":"1513_CR115","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1182\/blood-2021-144504","volume":"138","author":"DJ Kuter","year":"2021","unstructured":"Kuter DJ et al (2021) LUNA3 phase III multicenter, double-blind, randomized, placebo-controlled trial of the oral BTK inhibitor rilzabrutinib in adults and adolescents with persistent or chronic immune thrombocytopenia. Blood 138:1010. https:\/\/doi.org\/10.1182\/blood-2021-144504","journal-title":"Blood"},{"issue":"9","key":"1513_CR116","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS et al (2021) Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol 20(9):729\u2013738. https:\/\/doi.org\/10.1016\/S1474-4422(21)00237-4","journal-title":"Lancet Neurol"},{"issue":"7","key":"1513_CR117","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.3324\/haematol.2015.140806","volume":"101","author":"JR Brown","year":"2016","unstructured":"Brown JR et al (2016) Phase I study of single-agent CC-292, a highly selective Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory chronic lymphocytic leukemia. Haematologica 101(7):e295\u2013e298. https:\/\/doi.org\/10.3324\/haematol.2015.140806","journal-title":"Haematologica"},{"issue":"21","key":"1513_CR118","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1182\/blood.V122.21.1630.1630","volume":"122","author":"JR Brown","year":"2013","unstructured":"Brown JR et al (2013) Phase 1 study of single agent CC-292, a highly selective Bruton\u2019s tyrosine kinase (BTK) inhibitor, in relapsed\/refractory chronic lymphocytic leukemia (CLL). Blood 122(21):1630. https:\/\/doi.org\/10.1182\/blood.V122.21.1630.1630","journal-title":"Blood"},{"issue":"5","key":"1513_CR119","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/cts.13005","volume":"14","author":"M Kaul","year":"2021","unstructured":"Kaul M et al (2021) Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial. Clin Transl Sci 14(5):1756\u20131768. https:\/\/doi.org\/10.1111\/cts.13005","journal-title":"Clin Transl Sci"},{"issue":"10","key":"1513_CR120","doi-asserted-by":"publisher","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","volume":"63","author":"D Angst","year":"2020","unstructured":"Angst D et al (2020) Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem 63(10):5102\u20135118. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b01916","journal-title":"J Med Chem"},{"key":"1513_CR121","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13075-016-0988-z","volume":"18","author":"JK Park","year":"2016","unstructured":"Park JK et al (2016) HM71224, a novel Bruton\u2019s tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis. Arthritis Res Ther 18:91. https:\/\/doi.org\/10.1186\/s13075-016-0988-z","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"1513_CR122","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3899\/jrheum.200893","volume":"48","author":"MC Genovese","year":"2021","unstructured":"Genovese MC et al (2021) Safety and efficacy of poseltinib, Bruton\u2019s tyrosine kinase inhibitor, in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled, 2-part phase II study. J Rheumatol 48(7):969\u2013976. https:\/\/doi.org\/10.3899\/jrheum.200893","journal-title":"J Rheumatol"},{"issue":"7","key":"1513_CR123","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1021\/acs.jmedchem.9b00167","volume":"62","author":"SH Watterson","year":"2019","unstructured":"Watterson SH et al (2019) Discovery of branebrutinib (BMS-986195): a strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton\u2019s tyrosine kinase (BTK). J Med Chem 62(7):3228\u20133250. https:\/\/doi.org\/10.1021\/acs.jmedchem.9b00167","journal-title":"J Med Chem"},{"issue":"9","key":"1513_CR124","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1111\/bcp.14290","volume":"86","author":"IM Catlett","year":"2020","unstructured":"Catlett IM et al (2020) Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton\u2019s tyrosine kinase: randomised phase I, placebo-controlled trial in healthy participants. Br J Clin Pharmacol 86(9):1849\u20131859. https:\/\/doi.org\/10.1111\/bcp.14290","journal-title":"Br J Clin Pharmacol"},{"issue":"Supplement 1","key":"1513_CR125","doi-asserted-by":"publisher","first-page":"7004","DOI":"10.1182\/blood-2022-163596","volume":"140","author":"JA Woyach","year":"2022","unstructured":"Woyach JA et al (2022) Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated Bruton tyrosine kinase inhibitor for B-cell malignancies: updated analysis of the open-label phase 1\/2 dose-expansion BELLWAVE-001 study. Blood 140(Supplement 1):7004\u20137006. https:\/\/doi.org\/10.1182\/blood-2022-163596","journal-title":"Blood"},{"issue":"4","key":"1513_CR126","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3324\/haematol.2021.280061","volume":"107","author":"JN Allan","year":"2021","unstructured":"Allan JN et al (2021) Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton\u2019s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies. Haematologica 107(4):984\u2013987. https:\/\/doi.org\/10.3324\/haematol.2021.280061","journal-title":"Haematologica"},{"issue":"1","key":"1513_CR127","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3324\/haematol.2021.279158","volume":"107","author":"B Aslan","year":"2021","unstructured":"Aslan B et al (2021) Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica 107(1):292\u2013297. https:\/\/doi.org\/10.3324\/haematol.2021.279158","journal-title":"Haematologica"},{"issue":"1","key":"1513_CR128","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1124\/jpet.111.187740","volume":"341","author":"D Xu","year":"2012","unstructured":"Xu D et al (2012) RN486, a selective Bruton\u2019s tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents. J Pharmacol Exp Ther 341(1):90\u2013103. https:\/\/doi.org\/10.1124\/jpet.111.187740","journal-title":"J Pharmacol Exp Ther"},{"issue":"10","key":"1513_CR129","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1124\/dmd.111.040840","volume":"39","author":"L Liu","year":"2011","unstructured":"Liu L et al (2011) Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton\u2019s tyrosine kinase inhibitor. Drug Metab Dispos Biol Fate Chem 39(10):1840\u20131849. https:\/\/doi.org\/10.1124\/dmd.111.040840","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"1","key":"1513_CR130","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nchembio.481","volume":"7","author":"JA Di Paolo","year":"2011","unstructured":"Di Paolo JA et al (2011) Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol 7(1):41\u201350. https:\/\/doi.org\/10.1038\/nchembio.481","journal-title":"Nat Chem Biol"},{"issue":"16","key":"1513_CR131","doi-asserted-by":"publisher","first-page":"13023","DOI":"10.18632\/oncotarget.24310","volume":"9","author":"JC Byrd","year":"2018","unstructured":"Byrd JC et al (2018) First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget 9(16):13023\u201313035. https:\/\/doi.org\/10.18632\/oncotarget.24310","journal-title":"Oncotarget"},{"key":"1513_CR132","doi-asserted-by":"publisher","unstructured":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double\u2010blind, phase II trial - Cohen - 2020 - Arthritis & Rheumatology - Wiley Online Library Accessed: Oct. 07, 2024. [Online]. Available: https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/art.41275","DOI":"10.1002\/art.41275"},{"key":"1513_CR133","doi-asserted-by":"publisher","unstructured":"Tadmor T et al. (2024) BELLWAVE-011: phase 3 randomized trial of nemtabrutinib versus ibrutinib or acalabrutinib in untreated chronic lymphocytic leukemia\/small lymphocytic lymphoma. J Clin Oncol. 42(16_suppl):TPS7088\u2013TPS7088. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.TPS7088.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7088"},{"issue":"Supplement 1","key":"1513_CR134","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1182\/blood-2023-180485","volume":"142","author":"Y Song","year":"2023","unstructured":"Song Y et al (2023) A novel dual covalent and non-covalent next generation inhibitor of Bruton\u2019s tyrosine kinase LP-168 in patients with relapsed\/refractory B cell non-Hodgkin lymphoma: safety and efficacy results from a phase 1 study. Blood 142(Supplement 1):4400\u20134400. https:\/\/doi.org\/10.1182\/blood-2023-180485","journal-title":"Blood"},{"issue":"19","key":"1513_CR135","doi-asserted-by":"publisher","first-page":"14129","DOI":"10.1021\/acs.jmedchem.1c01279","volume":"64","author":"W Kawahata","year":"2021","unstructured":"Kawahata W et al (2021) Discovery of AS-1763: a potent, selective, noncovalent, and orally available inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem 64(19):14129\u201314141. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01279","journal-title":"J Med Chem"},{"issue":"Supplement 1","key":"1513_CR136","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1182\/blood-2024-210788","volume":"144","author":"N Timofeeva","year":"2024","unstructured":"Timofeeva N et al (2024) Impact of docirbrutinib (AS-1763) treatment in CLL: preclinical data and early clinical biomarkers. Blood 144(Supplement 1):1850\u20131850. https:\/\/doi.org\/10.1182\/blood-2024-210788","journal-title":"Blood"},{"key":"1513_CR137","doi-asserted-by":"publisher","unstructured":"Montoya S et al. (2024) Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1\/3 degrader NX-2127. Science. 383(6682):eadi5798. https:\/\/doi.org\/10.1126\/science.adi5798.","DOI":"10.1126\/science.adi5798"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01513-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01513-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01513-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:39:52Z","timestamp":1746193192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01513-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":137,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1513"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01513-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"27 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}